Higher preconception maternal and paternal vitamin B12 was tied to fewer birth defects in a Shanghai cohort of 3032 couples.
|Articles|October 31, 2012
ACIP: Vaccinate infants at risk for meningitis
Babies as young as 2 months at increased risk for meningococcal disease should be immunized with a new combination meningitis vaccine.
Advertisement
Advertisement
Related to this article
The FDA has approved Tivicay PD (dolutegravir) to treat HIV-1 in newborns from birth, based on IMPAACT 2023 pharmacokinetic and safety data.
Brian Vickery, MD, discusses a phase 1 trial evaluating the safety and tolerability of a microneedle stamp designed to deliver peanut protein through the skin.
The FDA approved tiratricol (Emcitate) for peripheral thyrotoxicosis in MCT8 deficiency, the first approved therapy for the rare disorder.
FDA accepts leniolisib sNDA with priority review for children with APDS aged 4+ weighing 13 to <27 kg; PDUFA date is January 30, 2027.
FDA approves oral ALK2 inhibitor zilurgisertib for FOP in patients 12+, based on phase 2 PROGRESS data on new heterotopic ossification volume.
The approval is based on BRAVE-AA-PEDS, in which 42% of adolescents receiving baricitinib 4 mg achieved at least 80% scalp hair coverage at week 36 vs 5% with placebo.
FDA approved obinutuzumab for relapsing or steroid-dependent childhood-onset INS, based on INShore data showing 95.5% vs 73.2% sustained remission.
Advertisement
Advertisement
Trending on Contemporary Pediatrics
1
FDA grants priority review to leniolisib sNDA for lower-weight children with APDS
2
FDA approves zilurgisertib for fibrodysplasia ossificans progressiva in patients aged 12 years and older
3
FDA approves obinutuzumab to reduce relapse risk in childhood-onset idiopathic nephrotic syndrome
4
FDA approves baricitinib for adolescents with severe alopecia areata
5